OTCMKTS:KALTF

Claritas Pharmaceuticals - KALTF Stock Forecast, Price & News

$0.01

0.00 (0.00%)

(As of 03/21/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.01
▼
$0.01
50-Day Range: $0.01
▼
$0.08
52-Week Range: $0.03
▼
$1.36

Volume: N/A
Average Volume: 9,705 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Claritas Pharmaceuticals (OTCMKTS:KALTF) Stock

Claritas Pharmaceuticals, Inc. engages in the development of next generation cannabinoid therapeutics. It also offers development programs for bone fracture healing, osteogenesis imperfecta, osteoporosis, and osteoporosis in Prader-Willi syndrome. The company was founded by Seth Yakatan on October 15, 2004 and is headquartered in San Rafael, CA.

Receive KALTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Claritas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALTF Stock News Headlines

March 17, 2023 | marketwatch.com

Generic Drugs Market Share, Segmentation and Forecast 2023-2028

February 14, 2023 | marketwatch.com

2023 Pharmaceutical CDMO Services Market Segmentation and Targeting: Strategies for Success Forecast till 2028

March 22, 2023 | Weiss Ratings (Ad)

Urgent Warning

This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …

February 13, 2023 | marketwatch.com

2023 Mifepristone Market Segmentation and Targeting: Strategies for Success Forecast till 2028

January 19, 2023 | marketwatch.com

Radioimmunotherapy Treatment Market Geographical Segmentation By Forecast Revenue 2023-2028

January 12, 2023 | finance.yahoo.com

Claritas Pharmaceuticals, Inc. (CLAZF)

January 5, 2023 | marketwatch.com

Online Pharmaceuticals Market Evolution Segmentation and Insight of Trends 2023 to 2028 with Top Countries Data

November 30, 2022 | marketwatch.com

Analgesics Market Global Investor, Latest Trends, Industry Growth, Size, Segmentation, Future Demands, by Regional Forecast to 2028

March 22, 2023 | Weiss Ratings (Ad)

Urgent Warning

September 30, 2022 | marketwatch.com

Pharmaceutical Sachet Market In 2022 : Industry Growth, Top Players, Segmentation and Forecast to 2028 with Top Countries Data

September 22, 2022 | finance.yahoo.com

New Claritas Report Reveals that the U.S. Hispanic Population Grew 89% Since 2000 – and Will Exceed 74 Million Consumers by 2028

September 13, 2022 | reuters.com

Claritas Pharmaceuticals Inc

May 11, 2022 | investing.com

Claritas Pharmaceuticals Inc (CLAS)

March 12, 2022 | benzinga.com

Kaya Now Appoints Stormy Simon As A Director Of The Board

February 22, 2022 | finance.yahoo.com

Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing

February 9, 2022 | finance.yahoo.com

Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022

January 26, 2022 | finance.yahoo.com

Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners

January 17, 2022 | finance.yahoo.com

Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns

January 17, 2022 | finance.yahoo.com

Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners

January 12, 2022 | seekingalpha.com

Claritas Pharmaceuticals signs $5M equity financing deal

January 12, 2022 | finance.yahoo.com

Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.

December 22, 2021 | finance.yahoo.com

Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

December 21, 2021 | finance.yahoo.com

Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

December 20, 2021 | finance.yahoo.com

Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

November 18, 2021 | finance.yahoo.com

Claritas Provides Update Regarding Phase 1 Clinical Study

November 4, 2021 | finance.yahoo.com

Claritas Announces Engagement of B. Riley Securities as Sponsor for the Company’s Planned Up-Listing of its Securities to the OTCQB

October 19, 2021 | finance.yahoo.com

Claritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLC

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive KALTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Claritas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALTF Company Calendar

Last Earnings: 11/29/2013
Today: 3/22/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:KALTF
Previous Symbol: OTCMKTS:QUEZF
CUSIP: N/A
CIK: N/A
Web: kalytera.co
Phone: (888) 861-2008
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Key Executives

Robert Edward Farrell
Chairman, President & Chief Executive Officer

Victoria Diana Rudman
Chief Financial Officer, Secretary & Treasurer

Nedira Frenkel
Director-Business Development

Key Competitors

View All Competitors

KALTF Stock - Frequently Asked Questions

How have KALTF shares performed in 2023?: Claritas Pharmaceuticals' stock was trading at $0.01 at the beginning of the year. Since then, KALTF shares have increased by 0.0% and is now trading at $0.01.
View the best growth stocks for 2023 here.
How were Claritas Pharmaceuticals' earnings last quarter?: Claritas Pharmaceuticals, Inc. (OTCMKTS:KALTF) issued its quarterly earnings results on Friday, November, 29th. The company reported ($0.40) earnings per share for the quarter.
When did Claritas Pharmaceuticals' stock split?: Claritas Pharmaceuticals's stock reverse split before market open on Friday, July 23rd 2021. The 1-20 reverse split was announced on Friday, July 23rd 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 23rd 2021. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Claritas Pharmaceuticals' stock symbol?: Claritas Pharmaceuticals trades on the OTCMKTS under the ticker symbol "KALTF."
How do I buy shares of Claritas Pharmaceuticals?: Shares of KALTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Claritas Pharmaceuticals' stock price today?: One share of KALTF stock can currently be purchased for approximately $0.01.
How can I contact Claritas Pharmaceuticals?: Claritas Pharmaceuticals' mailing address is 4040 Civic Center Drive, San Rafael, CA 94903. The official website for the company is kalytera.co. The company can be reached via phone at (888) 861-2008.

This page (OTCMKTS:KALTF) was last updated on 3/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial